EXAS
$104.91+0.99 (+0.95%)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Recent News
How Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment Story
On 13 March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services to expand access to Cologuard, an FDA-approved, non-invasive colorectal cancer screening test for average-risk adults 45 and older, integrating screening tools directly into pharmacy workflows. This collaboration highlights how pharmacy-based programs can broaden preventative cancer screening access, potentially reinforcing Exact Sciences’ role in closing colorectal cancer care gaps across...
Abbott to close $21B Exact Sciences acquisition Monday
Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.
1 Mid-Cap Stock to Consider Right Now and 2 Facing Headwinds
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Hedge Fund Beryl Capital Initiated a Position in CSG Systems Worth Over $54 Million. Is the Stock a Buy?
CSG Systems International delivers SaaS-based billing and customer engagement solutions to telecom and enterprise clients worldwide.
Exact Sciences Case Study Links Higher Screening Rates With Undervalued Shares
Exact Sciences has published a new case study on its collaboration with Amalgam Rx and Privia Health, focused on colorectal cancer screening. The program used EHR-integrated outreach and at-home noninvasive Cologuard tests to raise screening rates above national benchmarks. The initiative highlights a scalable approach to expanding access, supporting value-based care, and informing electronic quality measures. For investors watching Exact Sciences (NasdaqCM: EXAS), this case study...